Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 09:20 am Sale |
2023-12-31 | 13G | Cabaletta Bio, Inc. CABA |
Lynx1 Capital Management LP | 2,139,644 4.990% |
-686,332 (-24.29%) |
Filing History |
| 2024-02-14 09:19 am Purchase |
2023-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Lynx1 Capital Management LP | 122,198 9.900% |
51,841 (+73.68%) |
Filing History |
| 2024-02-14 09:19 am Sale |
2023-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Lynx1 Capital Management LP | 46 0.100% |
-114,511 (-99.96%) |
Filing History |
| 2024-02-14 09:18 am Sale |
2023-12-31 | 13G | Bionomics Limited BNOX |
Lynx1 Capital Management LP | 12,364,575 7.800% |
-533,400 (-4.14%) |
Filing History |
| 2023-11-13 4:55 pm Purchase |
2023-11-01 | 13G | C4 Therapeutics, Inc. CCCC |
Lynx1 Capital Management LP | 3,122,219 6.300% |
3,122,219 (New Position) |
Filing History |
| 2023-11-06 4:55 pm Purchase |
2023-10-26 | 13G | Stoke Therapeutics, Inc. STOK |
Lynx1 Capital Management LP | 2,664,158 6.000% |
2,664,158 (New Position) |
Filing History |
| 2023-10-30 4:21 pm Purchase |
2023-09-29 | 13G | Bionomics Limited BNOX |
Lynx1 Capital Management LP | 12,897,975 8.200% |
12,897,975 (New Position) |
Filing History |
| 2023-06-02 4:56 pm Purchase |
2023-05-31 | 13G | TScan Therapeutics, Inc. TCRX |
Lynx1 Capital Management LP | 5,224,600 12.200% |
5,224,600 (New Position) |
Filing History |
| 2023-02-14 4:07 pm Purchase |
2022-12-31 | 13G | Cabaletta Bio, Inc. CABA |
Lynx1 Capital Management LP | 2,825,976 9.700% |
465,664 (+19.73%) |
Filing History |
| 2023-02-14 4:06 pm Purchase |
2022-12-31 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 3,355,917 6.200% |
603,495 (+21.93%) |
Filing History |
| 2023-02-14 4:06 pm Purchase |
2022-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Lynx1 Capital Management LP | 70,357 7.600% |
22,550 (+47.17%) |
Filing History |
| 2023-02-14 4:05 pm Purchase |
2022-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN |
Lynx1 Capital Management LP | 3,126,173 6.800% |
1,588,828 (+103.35%) |
Filing History |
| 2023-01-23 4:28 pm Purchase |
2023-01-13 | 13G | Kinnate Biopharma Inc. KNTE |
Lynx1 Capital Management LP | 2,213,178 5.000% |
2,213,178 (New Position) |
Filing History |
| 2023-01-23 4:23 pm Purchase |
2023-01-13 | 13G | Pardes Biosciences, Inc. PRDS |
Lynx1 Capital Management LP | 3,139,202 5.000% |
3,139,202 (New Position) |
Filing History |
| 2022-12-30 4:29 pm Purchase |
2022-12-20 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Lynx1 Capital Management LP | 114,557 5.380% |
114,557 (New Position) |
Filing History |
| 2022-10-31 4:40 pm Purchase |
2022-10-20 | 13G | Cabaletta Bio, Inc. CABA |
Lynx1 Capital Management LP | 2,360,312 8.140% |
2,360,312 (New Position) |
Filing History |
| 2022-10-24 4:57 pm Purchase |
2022-10-13 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Lynx1 Capital Management LP | 47,808 5.100% |
47,808 (New Position) |
Filing History |
| 2022-09-29 4:30 pm Purchase |
2022-09-19 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 2,752,422 5.100% |
2,752,422 (New Position) |
Filing History |
| 2022-04-22 4:26 pm Purchase |
2022-04-14 | 13G | Alpine Immune Sciences, Inc. ALPN |
Lynx1 Capital Management LP | 1,537,345 5.100% |
1,537,345 (New Position) |
Filing History |